Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pharmaron Beijing Co., Ltd Regulatory Filings 2021

Apr 14, 2021

50881_rns_2021-04-14_3584d2fe-8065-4a03-a917-b5d7a6b15c0a.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [117 x 33] intentionally omitted <==

Pharmaron Beijing Co., Ltd. 康龍化成(北京)新藥技術股份有限公司*

(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 3759)

NOTICE OF BOARD MEETING

A meeting of the board of directors (the “ Board ”) of Pharmaron Beijing Co., Ltd.* (康龍化成(北 京)新藥技術股份有限公司) (the “ Company ”) will be held on Wednesday, April 28, 2021 for the purpose of, among other matters, considering and approving the first quarterly results of the Company and its subsidiaries for the three months ended March 31, 2021 and its publication.

By order of the Board Pharmaron Beijing Co., Ltd. 康龍化成(北京)新藥技術股份有限公司 Dr. Lou Boliang* Chairman

Beijing, the PRC April 14, 2021

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.

  • For identification purposes only